Joseph McCracken, MD
Hematology & Oncology · San Antonio, TXNPI 1023022365
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $550 of the $869 with a category attached, or 63.3%. Daiichi Sankyo Inc. accounts for 63.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $590 and has fallen 95.6% since, to $26 in 2025. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 15 payments — averaging $57.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$550
- Pharmacyclics LLC, An Abbvie Company$90
- Lilly USA, LLC$79
- Eisai Inc.$53
- Merck$41
- Puma Biotechnology, Inc.$22
- plus $33 from 2 others
Across 3 payments — averaging $1733.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$5K
What the payments were for
- Speaking & faculty fees$55063%
- Food & beverage$29334%
- Education$263%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 1 | $550 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $90 |
| Lilly USA, LLC | 2 | $79 |
| Eisai Inc. | 3 | $53 |
| Merck | 2 | $41 |
| Puma Biotechnology, Inc. | 1 | $22 |
| AstraZeneca | 1 | $19 |
| Amgen | 1 | $14 |
How this compares
$869 in reported general payments places this provider in the 30th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $10,793 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in San Antonio
- Timothy FenskeSan Antonio$626K
- Paul ShaughnessySan Antonio$470K
- Adolfo DiazSan Antonio$463K
- Francis GilesSan Antonio$436K
- John RenshawSan Antonio$430K
- Marcela Mazo-CanolaSan Antonio$257K
- Elizabeth Bowhay-CarnesSan Antonio$204K
- Nosha FarhadfarSan Antonio$117K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.